Wuhan General Group INC | WUHN Profile

Shares :

COMPANY PROFILE

WUHAN GENERAL GROUP INC.


SYMBOL :                                              WUHN

SECTOR :                                               PSYCH.

O/S :                                                        48 M

MARKET CAP :                                      $ 15 M

MARKET OPPORTUNITY :                   UP TO $350 B

WUHAN GENERAL GROUP INC. is the MOST UNDERVALUED company in the psychedelic market being one of the only companies in the world to have already carried out an in vitro / in vivo study with psilocybin in animals

Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands.

In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies

MAJOR DEVELOPMENT

WUHAN GENERAL GROUP INC. is currently in Pre-enrolment Patient- screening for Phase 1 Human trial.

VERY SMALL FLOAT

WUHAN GENERAL GROUP INC. O/S is ONLY 48 millions with a small float of 10 millions

COMPANY BRIEF

 

| Researching and developing indications for psilocybin new therapies

| Researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands

| Currently in Pre-enrolment Patient- screening for Phase 1 Human trial.

| Cosmetics and FSMP company with cannabinoid and psilocybin research, formulation and delivery system divisions

HIGHLIGHTS

 

| First in market  to research psilocybin for treatment of alcoholism and cardiovascular tissue 

| Established distribution channels in the US, Canada, Europe and Africa 

| Early stage entry into cannabinoid and psilocybin company- Enormous upside

| Research undiscovered properties of cannabinoids for treatment of respiratory infectious diseases 

M2BIO DEVELOPMENT

WUHAN infused beverages MEDSPRESSO

WUHAN Cosmetics and food name Dr. AnnaRx

WUHAN COMPARABLE

RVV | OTC

JOIN FACEBOOK INVESTOR GROUP

Wuhan last news | article

Investors: If you like Compass Pathways you will love M2Bio Sciences.

For several weeks now, no one can dispute that the psychedelics market is one of the hottest. Several IPOs since spring (MMED, NUMI, TRIP …) have taken the market to…

Psychedelic highlights | September 21 – 25

Psychedelic highlights | September 21 – 25 1. COMPASS Pathways | CMPS can’t be stopped and has reached new heights this week. Compass Pathways continues its strong growth following its…

M2Bio Sciences | WUHN enters cannabis production and projects nearly $10M (us) in revenue for the first year

M2Bio Sciences, Inc | WUHN on OTC Earlier this week, M2Bio Sciences Inc | WUHN, which is already involved in research and development for psilocybin new therapies that will help patients who…

Wuhan General Group Corporate Update on Tsime Pharmaceuticals Acquisition

CAPE TOWN, SA / ACCESSWIRE / September 22, 2020 / WUHAN GENERAL GROUP, INC. (WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is…

Psychedelic highlights | Sept. 14 – 18

Psychedelic highlights | September 14 – 18 1. COMPASS Pathways | CMPS enter the market with a value of 1.2 billion and announces pricing of upsized initial public offering Compass…

Psychedelic highlights | August 31 – 04

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most…

M2Bio Sciences | An opportunity in the psychedelic and cannabinoids market

M2Bio Sciences, Inc | WUHN on OTC Who are M2Bio Sciences ? M2Bio Sciences | WUHN through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes…

The psychedelics market, still some bargains ?

According to Cannacord’s most recent report on the psychedelics market, the value of the market is more than $100 billion. Some companies are approaching billions of dollars (CAD) in valuation.…

Wuhan General Group Corporate Update | WUHN (OTC)

M2Bio Sciences, Inc | WUHN on OTC (Wuhan General Group) CAPE TOWN, SA / ACCESSWIRE / August 21, 2020 / WUHAN GENERAL GROUP, INC. (OTC Pink:WUHN) (“Wuhan” or the “Company”), a bioceutical…

Why M2Bio Sciences | WUHN is a stock to watch ?

M2Bio Sciences, Inc | WUHN on OTC (Formely Wuhan General Group) For several weeks now, a penny stock has started opening the eyes of investors and it is not over.…

Psychedelic highlights | July 31 – 04

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most…

M2Bio Sciences, Inc (Wuhan General Group) Signs MOA for the Acquisition of Tsime Pharmaceuticals (PTY) Limited

M2Bio Sciences, Inc | WUHN on OTC (Formely Wuhan General Group) CAPE TOWN, SA / ACCESSWIRE / July 17, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the…


Shares :